- Home
- DMRC vs ANTX Comparison
DMRC vs ANTX Comparison
Compare DMRC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DMRC | ANTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 170.6M |
| IPO Year | 2008 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DMRC | ANTX |
|---|---|---|
| Price | $8.61 | $4.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $2.00 |
| AVG Volume (30 Days) | 158.5K | ★ 310.6K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.58 | ★ 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.69 | N/A |
| 52 Week Low | $4.07 | $1.00 |
| 52 Week High | $14.64 | $6.91 |
Technical Indicators
Market Signals| Indicator | DMRC | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 62.07 |
| Support Level | $7.82 | $1.06 |
| Resistance Level | $8.93 | $5.11 |
| Average True Range (ATR) | 0.56 | 0.36 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 98.12 | 64.33 |
Price Performance
Historical ComparisonAbout DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.